公开(公告)号：EP4440546A1

公开(公告)日：2024-10-09

申请号：EP22847214.8

申请日：2022-12-04

Applicant: Incyte Corporation

Inventor： MODEPALLI, Naresh ,  SHETH, Trupti ,  BROWN, Marc ,  EVANS, Charles ,  FIDGE, James ,  GUIDALI, Florencia ,  MCINTOSH, Tecashanell ,  COFRE, Vanessa

IPC: A61K9/00 ,  A61K9/107 ,  A61K9/113 ,  A61K9/70 ,  A61K47/10 ,  A61K47/18 ,  A61K31/4155 ,  A61K31/519 ,  A61P17/00 ,  A61P17/06 ,  A61P17/10 ,  A61P17/12 ,  A61P17/14

CPC classification number: A61K9/0014 ,  A61K47/18 ,  A61K9/7015 ,  A61K9/107 ,  A61K47/10 ,  A61K31/519 ,  A61P17/00 ,  A61P17/06 ,  A61P17/10 ,  A61P17/12 ,  A61P17/14 ,  A61K9/0017 ,  A61K9/113

公开(公告)号：EP4431528A1

公开(公告)日：2024-09-18

申请号：EP21961862.6

申请日：2021-10-29

Applicant: Longbio Pharma (Suzhou) Co., Ltd.

Inventor： SUN, Nai-Chau ,  SUN, Chow-Rou-Yun ,  MA, Haili ,  LIU, Yunhua ,  YANG, Hongzhou ,  GUO, Ruowen ,  GAO, Qi ,  LIU, Heng

IPC: C07K16/42 ,  C07K16/28 ,  C12N15/63 ,  A61P37/08 ,  A61K47/18 ,  A61K39/395 ,  A61K39/00 ,  A61P11/06

CPC classification number: A61K39/00 ,  A61K39/395 ,  A61K47/18 ,  A61P11/06 ,  A61P37/08 ,  C07K16/28 ,  C07K16/42 ,  C12N15/63

Abstract: The present application relates to an antigen binding protein comprising at least one CDR of a heavy chain variable region and at least one CDR of a light chain variable region, wherein said heavy chain variable region comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 73 or 74, and the light chain variable region comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 75 or 76.

公开(公告)号：EP4426347A1

公开(公告)日：2024-09-11

申请号：EP22814311.1

申请日：2022-11-04

Applicant: AstraZeneca UK Limited

Inventor： SCHMELZER, Albert ,  PATEL, Sajal ,  MEDINA, Annette ,  GALLEGOS, Austin

IPC: A61K39/395 ,  A61K31/00

CPC classification number: A61K39/39591 ,  A61K47/26 ,  A61K47/18 ,  A61K9/0019 ,  A61P37/00

公开(公告)号：EP4424313A1

公开(公告)日：2024-09-04

申请号：EP22887110.9

申请日：2022-10-27

Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： KANOH Takeo ,  TAKAHASHI Shodai ,  MAEDA Yuki ,  HASHIMOTO Shota

IPC: A61K31/5377 ,  A61K9/10 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K47/46 ,  A61P35/00 ,  A61P43/00

CPC classification number: A61P43/00 ,  A61K47/20 ,  A61K47/22 ,  A61K31/5377 ,  A61K9/10 ,  A61K47/02 ,  A61K47/46 ,  A61K47/12 ,  A61P35/00 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K47/18

Abstract: The present invention relates to a syrup containing alectinib or a salt thereof. The present invention provides a syrup containing alectinib or a salt thereof, which is a poorly water-soluble agent, and having improved fluidity and/or palatability. The syrup of the present invention has a plasma concentration profile equivalent to or greater than, or is biologically equivalent to, a capsule containing the same amount of alectinib or a salt thereof as the syrup, or has an enhanced oral bioavailability compared to a capsule containing the same amount of alectinib or a salt thereof as the syrup.

公开(公告)号：EP4395815A1

公开(公告)日：2024-07-10

申请号：EP22863830.0

申请日：2022-09-02

Applicant: Dr. Reddy's Laboratories Limited

Inventor： JAYARAMAN, Murali ,  K GOUD, Saisharan ,  ASHOK NANKAR, Sunil ,  NANATH, Maya ,  SIGIREDDI, Indra Kumar ,  AGGARWAL, Lovisha ,  KALIGATLA, Sireesha Goswamy ,  MARIKANTY, Ravi Kumar ,  S, Abirami ,  SIVALANKA, Giridhar ,  PENMETSA, Ravi Kiranmai ,  LABALA, Suman ,  INGALE, Mahesh ,  SARKAR, Puja ,  DESAI, Mayur Vijay ,  KIRAVE, Prathibha Chandrashekhar ,  SHINDE, Chetan Govindrao

IPC: A61K39/00 ,  A61K47/00 ,  C07K16/00

CPC classification number: C07K2317/2120130101 ,  C07K2317/7620130101 ,  C07K2317/9420130101 ,  C07K16/2818 ,  A61K39/39591 ,  A61K47/18 ,  A61K47/12 ,  A61K47/26 ,  A61K47/183 ,  A61K9/08

公开(公告)号：EP4339212A3

公开(公告)日：2024-06-19

申请号：EP23206430.3

申请日：2010-07-28

Applicant: F. Hoffmann-La Roche AG

Inventor： ADLER, Michael ,  GRAUSCHOPF, Ulla ,  MAHLER, Hanns-Christian ,  STAUCH, Oliver Boris

IPC: A61K9/00 ,  A61K9/19 ,  A61K38/47 ,  A61K39/395 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/00 ,  A61P35/04 ,  C07K16/32

CPC classification number: A61K9/19 ,  A61K39/39591 ,  A61K47/18 ,  A61K47/183 ,  A61K47/26 ,  A61K47/42 ,  C07K16/32 ,  A61K9/0019 ,  A61K38/47 ,  C12Y302/01035 ,  A61K47/20 ,  A61P35/00 ,  A61P35/04

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

公开(公告)号：EP4331681A3

公开(公告)日：2024-05-22

申请号：EP24150035.4

申请日：2019-03-14

Applicant: Kabushiki Kaisha Toshiba

Inventor： ISHIHARA, Mitsuko ,  AKAHOSHI, Eiichi ,  NAITO, Katsuyuki ,  NOZAKI, Emi ,  SARUWATARI, Saeko

IPC: A61P43/00

CPC classification number: A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K45/00 ,  A61K47/24 ,  A61K47/18 ,  A61K47/22 ,  A61K48/00 ,  A61P43/00 ,  C07C229/24 ,  C07D233/02 ,  C07D243/08 ,  C07D251/04 ,  C07D295/15 ,  C07D295/13 ,  C07D211/14 ,  C07D241/04 ,  A61K9/1272

Abstract: The present embodiment provides a method for delivering activators to cells, wherein said activator containing lipid particles are brought into contact with the cells,
where a compound represented by the formula (1):

         Q-CHR2     (1)

wherein
Q is represented by the following formula (1-Q):

         RQ12N-(CRQ22)q1-NRQ1-(CRQ22)q2-*     (1-Q)

wherein
each RQ1 is independently an alkyl,
each RQ2 is independently hydrogen or an alkyl,
any two of RQ1s and RQ2s may link together to form a nitrogen-containing alicyclic ring,
q1 is an integer of 1 to 4,
q2 is an integer of 0 to 4, and
the mark * indicates the position bonding to -CHR2; and
each R is independently an aliphatic group of C12 to C24;
wherein said R is represented by the following formula (1-R):

         -LR1-C(=O)-O-LR2     (1-R)

where
LR1 is alkylene and
LR2 is represented by the following formula (1-R2):

         -CH2-CH=CH-(CH2)r2-H     (1-R2)

where r2 is an integer of 1 to 10.

公开(公告)号：EP4360652A2

公开(公告)日：2024-05-01

申请号：EP24160547.6

申请日：2017-11-03

Applicant: Takeda Pharmaceutical Company Limited

Inventor： FIEDLER, Christian ,  FRITSCHER, Eva ,  HASSLACHER, Meinhard ,  MITTERGRADNEGGER, Dominik ,  TABISH, Tanvir

IPC: A61K47/26

CPC classification number: A61K31/195 ,  A61K35/76 ,  A61P7/00 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61K47/02 ,  A61K47/18 ,  C12N15/86

Abstract: Adeno-associated liquid and lyophilized pharmaceutical compositions are provided herein. In exemplary aspects, the pharmaceutical compositions comprise about 5 mM to about 25 mM L-histidine, about 0 mM to about 150 mM sodium chloride, about 0.001 % (w/v) to about 0.01 % (w/v) polysorbate 80 (PS80), and about 1 % to about 10% (w/v) sucrose, trehalose, or combination thereof to AAV. In exemplary aspects, the pharmaceutical compositions further comprise glycine or mannitol. Methods of preparing a pharmaceutical composition comprising AAV, methods of treating a bleeding disorder in a subject, and methods of storing AAV compositions are also provided.

公开(公告)号：EP4360622A1

公开(公告)日：2024-05-01

申请号：EP22827682.0

申请日：2022-06-24

Applicant: Shanghai Aurora Biotechnology Co., Ltd.

Inventor： CHEN, Zhixiang ,  CHEN, Bangyin ,  LIU, Shuang ,  GUO, Zhen ,  FU, Jun ,  WANG, Tingting ,  YING, Shuhuan

IPC: A61K9/08 ,  A61K31/407 ,  A61K47/18 ,  A61P29/00

CPC classification number: A61P29/00 ,  A61K47/40 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K31/407 ,  A61K47/18 ,  A61K9/08

Abstract: A ketorolac liquid composition, a preparation method therefor, and an application thereof. Provided is a ketorolac liquid composition, comprising the following components: ketorolac tromethamine, a stabilizer, a buffer, an osmotic pressure regulator, and a pH regulator; the ketorolac liquid composition does not contain ethanol; a concentration of ketorolac tromethamine is 0.15 mmol/L-160.00 mmol/L, and the concentration refers to a ratio of a molar amount of the ketorolac tromethamine to a volume of the ketorolac liquid composition. The ketorolac liquid composition does not contain an organic solvent, has stable physical and chemical properties, has less in-vivo irritation, has a lower adverse reactions, is safer and more convenient, can improve medication compliance of patients and the convenience of clinical administration, and has good market prospects.

公开(公告)号：EP4056234B1

公开(公告)日：2024-04-17

申请号：EP21162437.4

申请日：2021-03-12

IPC: A61Q11/00 ,  A61K9/08 ,  A61K33/30 ,  A61K47/18 ,  A61K47/20 ,  A61P31/14

CPC classification number: A61K9/0043 ,  A61K9/006 ,  A61K47/20 ,  A61K47/18 ,  A61K9/08 ,  A61K9/007 ,  A61K33/30 ,  A61P31/14 ,  A61Q11/00 ,  A61K31/20 ,  A61K31/185 ,  A61K8/44 ,  A61K8/447 ,  A61K8/463 ,  A61K2800/59620130101